Diabetic Retinopathy

Diabetic retinopathy is one of the cleaner secondary claims in the system, and that's exactly why so many of them go sideways. When diabetes is already service-connected, the nexus from diabetes to the retinopathy is usually straightforward. The eye disease is a recognized complication of the underlying disease. The General Counsel and the regulation at 38 CFR § 3.310 treat complications of a service-connected condition as service-connected in turn. So the question that decides most of these claims is not whether the condition is connected. It's how bad the vision loss is, and whether the C&P exam actually measured it.

That's where the file falls apart. Diabetic retinopathy is rated under 38 CFR § 4.79, DC 6006, on visual impairment. Visual impairment means two things measured together: visual acuity and visual field. The rating runs through the General Rating Formula for Diseases of the Eye, which routes the number to the acuity-and-field tables. The alternative path, and the one most veterans should be looking at, is incapacitating episodes counted as treatment visits over the past 12 months. If the exam records corrected acuity in one eye and skips the visual field testing, or skips the field testing in both, the rating is built on half the picture. In Claim Raven's analysis of the dataset, that incomplete-exam problem is the single most common reason these cases get sent back.

This page walks through DC 6006 and the General Rating Formula, how acuity and field combine into a number, the treatment-visit path that reaches 60 percent, the clinical markers that drive severity (proliferative retinopathy, macular edema, laser photocoagulation, anti-VEGF injections, vitrectomy), what the C&P examiner has to measure, and the secondary chain back to diabetes that makes this claim winnable in the first place.

TL;DR

• Diabetic retinopathy is rated under 38 CFR § 4.79, DC 6006 (retinopathy or maculopathy), on visual impairment through the General Rating Formula for Diseases of the Eye.
• Visual impairment is scored from two inputs measured together: visual acuity (the eye chart) and visual field (peripheral vision, by Goldmann or automated perimetry), or on incapacitating episodes, whichever produces the higher rating.
• The old "minimum 10% during active pathology" rule is gone. VA rewrote § 4.79 effective 2018-05-13 and that phrase appears nowhere in the current Part 4. It was replaced by something considerably better: an incapacitating-episodes ladder counted in treatment visits, reaching 60% at 7 or more visits in 12 months.
• Anti-VEGF injections count as treatment visits. Note (2) to the formula names intravitreal and periocular injections as examples of treatment, and Note (1) defines an incapacitating episode as a condition severe enough to require a clinic visit specifically for treatment. A veteran on a monthly injection schedule has 12 qualifying visits a year.
• This is almost always a secondary condition to service-connected diabetes mellitus under 38 CFR § 3.310. When diabetes is service-connected, the nexus is usually straightforward and the dispute is over severity.
• The clinical markers that drive severity are proliferative diabetic retinopathy, macular edema, and treatment history: laser photocoagulation, anti-VEGF injections, and vitrectomy.
• The eye rates separately from the diabetes rating itself. Retinopathy does not get folded into the diabetes percentage.
• Acuity is rated on best-corrected vision (with glasses), not uncorrected, with limited exceptions.
• In Claim Raven's analysis of 557 BVA diabetic retinopathy cases, 35.9% were remanded, 22.6% granted, and 24.6% denied. Of the 417 cases with a C&P adequacy determination, 48.7% had the exam flagged as inadequate.

DC 6006 and the General Rating Formula for Diseases of the Eye

Diabetic retinopathy lives under 38 CFR § 4.79, DC 6006, which covers retinopathy or maculopathy. Unlike the orthopedic codes, DC 6006 does not carry its own table of percentages tied to a measurement of the disease itself. Instead it routes through the General Rating Formula for Diseases of the Eye. That formula gives you two paths, and you take whichever pays more:

Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation.

The incapacitating-episodes path is a tiered schedule based on how many treatment visits you have over a 12-month period, and for diabetic retinopathy under active management it is frequently the higher-paying path. Here it is verbatim:

Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation

With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months, 60%

With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months, 40%

With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months, 20%

With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months, 10%

Two notes define the terms. Note (1) says an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes. Note (2) gives examples of qualifying treatment, and they include intravitreal and periocular injections.

Read those together and the practical consequence is large. "Incapacitating episode" sounds like it should mean bed rest or hospitalization. It does not. It means a treatment visit. A veteran on a monthly anti-VEGF injection schedule for macular edema has twelve qualifying visits in twelve months, which is comfortably past the seven-visit threshold for 60 percent, and that evaluation is available even if corrected acuity is 20/40 and the visual field is full.

If you have read that active retinopathy carries a "minimum 10 percent," that rule is gone. VA rewrote the eye schedule effective May 13, 2018, and the phrase "active pathology" no longer appears anywhere in 38 CFR Part 4. The underlying idea survived, in a much more generous form: active disease under ongoing treatment is compensable regardless of acuity, but the ceiling is 60 percent rather than a 10 percent floor.

The practical instruction follows directly. Count and date the visits. An injection log, an infusion or procedure record, or a printout of ophthalmology encounters over the past twelve months is the single highest-value document on this claim, and it is one most veterans never think to submit because nothing in the process asks for it.

The visual-impairment path is where the higher numbers come from, and it is the path the exam either supports or sabotages.

How Visual Acuity and Visual Field Build the Number

Visual impairment under § 4.79 is not one measurement. It is the combination of two: how well you see straight ahead (acuity) and how much peripheral vision you have (field). The regulation evaluates both, then combines them, and the higher of the acuity-based or field-based result drives the rating.

Visual acuity. Acuity is measured on the standard chart and rated on best-corrected vision, meaning with your glasses or contacts on, with narrow exceptions. The tables in 38 CFR § 4.79 and § 4.76a/§ 4.77 step the rating up as central acuity worsens, and the rating depends on the acuity in both eyes together. A veteran with 20/40 in each eye sits at the low end. As the worse eye drops toward 20/100, 20/200, and counting-fingers or light-perception-only, the percentage climbs, and a markedly worse eye paired with a good fellow eye still produces a meaningful rating. Diabetic macular edema is the classic driver of central acuity loss, because the swelling sits in the macula, which is the part of the retina responsible for sharp central vision.

Visual field. Field is the other half. Proliferative diabetic retinopathy, the scarring from extensive laser photocoagulation (panretinal photocoagulation deliberately destroys peripheral retina to save the center), and vitreous hemorrhage can all contract the peripheral field even when central acuity reads well on the chart. Field loss is measured by perimetry. The rating converts the field findings into an impairment value that competes with the acuity value, and the higher one wins. This is why a veteran with decent acuity but heavily treated proliferative disease can still rate higher than the acuity table alone would suggest, but only if someone actually ran the perimetry.

The practical takeaway: a rating built on acuity alone is incomplete by regulation. Field is not optional. When the C&P exam skips it, the rating is being decided on half the evidence.

The Clinical Markers That Drive Severity

The severity of diabetic retinopathy, and therefore the rating ceiling, tracks a clinical progression that the medical record should document explicitly. These are the markers a rater and the Board look for:

Proliferative diabetic retinopathy (PDR). This is the advanced stage, where abnormal new blood vessels grow on the retina and into the vitreous. PDR is the stage most associated with serious vision loss, vitreous hemorrhage, and retinal detachment. Documentation that the disease has reached the proliferative stage signals the kind of field and acuity loss that supports a higher rating.

Diabetic macular edema (DME). Fluid and swelling in the macula. DME is the leading cause of central acuity loss in diabetic eyes, and central acuity is what the eye chart measures. DME with documented acuity loss is the cleanest path to a higher acuity-based rating.

Treatment history. The treatments are evidence of severity in their own right, and they should be in the file with dates:

• Laser photocoagulation, including panretinal photocoagulation for proliferative disease, which by design sacrifices peripheral field.
• Anti-VEGF injections (for example the drugs ending in -zumab/-cept given intravitreally), typically for macular edema or proliferative disease, often on an ongoing schedule. Each injection is a treatment visit, so an ongoing schedule builds the visit count that drives the incapacitating-episodes ladder, even when vision is stable.
• Vitrectomy, surgery to remove vitreous hemorrhage or address tractional detachment, which marks advanced disease.

A file that records "diabetic retinopathy, stable" without staging, without acuity and field numbers, and without a dated treatment-visit count gives the rater almost nothing to work with. A file that documents PDR, recurrent DME, a history of panretinal laser, and a year of anti-VEGF injections tells a severity story the rating tables can actually price.

The Secondary Chain: Diabetes to the Eye

Diabetic retinopathy is, by definition, a complication of diabetes. The whole reason it carries the word "diabetic" is the causal mechanism: chronic hyperglycemia damages the small blood vessels of the retina. Under 38 CFR § 3.310, a condition caused or aggravated by a service-connected disability is service-connected as a secondary. Aggravation as a basis was confirmed in Allen v. Brown.

When diabetes is already service-connected, the nexus for the retinopathy is usually the easy part. The medical literature treats diabetic retinopathy as a direct microvascular complication, and an ophthalmology or optometry record that diagnoses diabetic retinopathy in a veteran with established diabetes generally carries the connection. The nexus opinion does not have to do heavy lifting here the way it does in a knee-to-back gait-compensation theory. The diagnosis itself names the cause.

That is exactly why the contested issue migrates to severity. The VA grants the connection, assigns an acuity-based number or a visit-count number, and the real dispute becomes whether the exam captured the full extent of the vision loss and the treatment history. The eye rates separately from the diabetes percentage itself, so the retinopathy rating is additive to the diabetes rating in the combined-ratings math under § 4.25, not absorbed into it.

The same diabetic microvascular and end-organ logic opens other secondaries off the same root disease: peripheral neuropathy in the extremities, kidney disease, and cardiovascular conditions. The eye is one branch of a larger tree, and a veteran working a diabetic retinopathy claim should look at the whole branch structure rather than the single leaf. The secondary conditions tool maps the chains off diabetes.

C&P Exam Mechanics: What the Examiner Has to Measure

The eye C&P exam follows the DBQ for eye conditions, and the rating is only as good as the measurements in it. For diabetic retinopathy, the examiner needs to record:

• Best-corrected central visual acuity in each eye, with the correction noted, not just uncorrected vision.
• Visual field testing by Goldmann kinetic perimetry or automated (for example Humphrey) perimetry, with the plotted results, in each eye.
• Staging of the retinopathy: nonproliferative versus proliferative, and presence or absence of macular edema.
• Treatment history with dates and a total count: laser photocoagulation, anti-VEGF injections, vitrectomy. The number of treatment visits in the past 12 months is a rating criterion in its own right, so the count matters as much as the fact of treatment.
• Whether the disease is active and under ongoing treatment, and how many clinic visits that treatment required over the past year.
• Incapacitating episodes over the past 12 months, for the alternative rating path.

When all of this is in the report, the rater can run the visual-impairment path and the treatment-visit path and take whichever is higher, which is what the formula directs. When the exam is sparse, the rater defaults downward. The cases that come back inadequate in the dataset typically show the same missing components: acuity without field testing, field testing without proper perimetry plots, no staging, or no documentation of the treatment that would establish active disease. Each gap is a place where a rating that should have been assigned was not.

Common Evidence Gaps in Diabetic Retinopathy Claims

A few patterns I see across BVA decisions involving diabetic retinopathy.

Visual field never tested. This is the dominant gap. The exam records corrected acuity and stops. Because the rating is supposed to take the higher of the acuity-based and field-based results, an exam with no perimetry can only produce an acuity number. A veteran with extensive panretinal laser and contracted peripheral fields gets rated as if the field loss did not exist. With 48.7 percent of the cases that had a C&P adequacy determination flagged as inadequate, the missing or incomplete eye exam is doing a lot of the work behind that figure.

Severity frozen at one snapshot. Diabetic retinopathy progresses. An exam from three years ago that found mild nonproliferative disease does not describe a veteran who has since developed macular edema and started anti-VEGF injections. When the file is not updated, the rating lags the disease. The remand pattern in the dataset, the most common single outcome at 35.9 percent, is consistent with the Board sending cases back to capture progression the original exam missed.

No staging or treatment timeline. A note that says "diabetic retinopathy" without distinguishing nonproliferative from proliferative, without noting macular edema, and without the laser and injection dates leaves the rater unable to price severity. The treatment history is severity evidence. When it is absent, the claim drifts downward regardless of how advanced the disease actually is, and the visit count that could have carried it to 40 or 60 percent is never assembled.

The treatment-visit path never run. Some decisions rate a veteran with stable corrected acuity at zero, never counting the ongoing anti-VEGF injections or repeat laser treatments that the General Rating Formula treats as incapacitating episodes. The formula requires evaluating both paths and taking the higher, and seven qualifying visits in twelve months reaches 60 percent. Note that decisions issued before 2018-05-13 applied the old "minimum 10 percent during active pathology" rule instead, so older cases in the dataset describe a different and much lower ceiling.

Best-corrected versus uncorrected confusion. Acuity is rated on best-corrected vision with limited exceptions. A record that only captures uncorrected acuity, or mixes the two, muddies the rating input and invites either an inflated or deflated number that does not survive review.

I don't know the exact percentage of diabetic retinopathy claims that carry one or more of these gaps. What I can say from Claim Raven's analysis of 557 BVA diabetic retinopathy cases is that 35.9 percent were remanded, 22.6 percent granted, and 24.6 percent denied, and that of the 417 cases with a C&P adequacy determination, 48.7 percent had the exam flagged as inadequate. That nearly-half-inadequate rate, paired with remand as the most common outcome, fits the picture in this post: the connection to diabetes is usually accepted, and the fight is over an eye exam that did not measure everything the rating tables need.

Bottom Line

Diabetic retinopathy ratings turn on a paradox. The hard part of most claims, the nexus, is usually easy here because the disease is a recognized complication of service-connected diabetes under § 3.310. The easy-sounding part, the rating number, is where these claims actually live or die, because DC 6006 routes through the General Rating Formula for Diseases of the Eye and demands two measurements, acuity and visual field, taken together, with a 10 percent floor whenever the disease is active and under continuous treatment. The cases that come out right have a complete eye exam: best-corrected acuity in each eye, real perimetry, clear staging of nonproliferative versus proliferative disease and macular edema, and a dated treatment history of laser, anti-VEGF injections, and any vitrectomy. The cases that get remanded, which is the most common outcome in the dataset, tend to be the ones where the field testing never happened or the exam captured a snapshot the disease had already outgrown. Same eye, different paper trail, different rating.

Related Conditions

Diabetic retinopathy connects most directly to diabetes, the service-connected root that makes the secondary nexus straightforward. It shares the § 4.79 visual-impairment rating mechanics with other eye conditions, including cataracts (which diabetics develop earlier and more often), glaucoma, and dry eye. Veterans working a diabetic retinopathy claim should also look at the broader set of diabetic complications, including peripheral neuropathy and kidney disease, and use the secondary conditions tool to map the full chain off diabetes before assuming one eye rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.79, DC 6006, and the General Rating Formula for Diseases of the Eye, with visual-impairment evaluation under the acuity and field provisions of § 4.76a and § 4.77. Secondary service connection from § 3.310. Combined ratings math from § 4.25. Case law on secondary aggravation from Allen v. Brown.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 557 diabetic retinopathy cases. Within that subset, outcomes ran 35.9% remanded, 22.6% granted, and 24.6% denied. Of the 417 cases with a C&P adequacy determination, 48.7% had the examination flagged as inadequate. The dataset captures overall outcome rather than a per-measurement (acuity versus field) breakdown.
• Classification approach: Diagnostic code and rating-formula definitions drawn from the regulatory text. Severity markers (proliferative retinopathy, macular edema, laser photocoagulation, anti-VEGF injections, vitrectomy) reflect the clinical staging that the regulation's visual-impairment tables depend on. Secondary-connection analysis follows § 3.310.
• Limitations:
• Compensation depends on best-corrected acuity and visual field measurements that must come from a complete eye exam. Without both, the rating is built on partial evidence.
• The 10% active-disease minimum applies during active pathology requiring continuous treatment. Whether a given course of treatment qualifies as "active" can be contested.
• Diabetic retinopathy progresses over time, so a rating reflects the exam date, not necessarily current severity.
• Selection bias: BVA-level patterns reflect cases that appealed. Most diabetic retinopathy claims resolve at the RO level and are not in any BVA dataset.
• Application of the visual-field evaluation rules at the RO level is uneven, which is part of why field testing is the most common gap.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.